Are Ozempic, Wegovy and Rybelsus the same thing?

All three contain semaglutide as their active ingredient. They differ in dose strength, what they are licensed for, and how they are taken. Ozempic is licensed for type 2 diabetes (injectable, up to 2 mg weekly). Wegovy is licensed for weight management (injectable, 2.4 mg weekly). Rybelsus is an oral tablet (14 mg daily) licensed for type 2 diabetes.

How does semaglutide cause weight loss?

Semaglutide is a GLP-1 receptor agonist. It mimics a natural gut hormone that signals satiety and slows gastric emptying. Over weeks of weekly injection, it reduces appetite and food intake — clinical trials at the 2.4 mg dose produced around 15% mean weight reduction over 68 weeks.

Does semaglutide help the heart?

Yes — and this is one of the most important recent findings. The SELECT trial (NEJM 2023) showed semaglutide reduced major cardiovascular events by ~20% over almost 4 years in adults with overweight or obesity and established cardiovascular disease. That benefit appears to be larger than what weight loss alone would predict.

How long does it take to work?

Some appetite reduction is noticeable within the first 2-4 weeks. Meaningful weight loss generally becomes visible by month 3, with peak average weight loss reached around month 12-16 on the maintenance dose. Discontinuation is followed by substantial weight regain — typically two-thirds of the lost weight within a year of stopping.

What is GLP-1 semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist — a lab-made, long-acting version of the natural gut hormone GLP-1 (glucagon-like peptide-1). It is the active ingredient in three MHRA-licensed UK medicines: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management.

What is Semaglutide? Plain-English UK Explainer (2026)

GLP-1 semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist — a chemically modified, long-acting copy of a natural gut hormone. In the UK it is sold as three MHRA-licensed prescription medicines built on the same active ingredient: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management.

Key facts

One molecule, three brands — Ozempic, Wegovy and Rybelsus all contain semaglutide; only the dose and formulation differ.
~15% mean weight reduction at 68 weeks on the 2.4 mg dose (STEP-1 trial).
~20% reduction in major cardiovascular events in adults with obesity or overweight and established cardiovascular disease (SELECT trial, NEJM 2023).
Once-weekly dosing — semaglutide is engineered to last about a week, versus a few minutes for natural GLP-1.

What is semaglutide, in one paragraph?

Semaglutide is the molecule behind three Novo Nordisk medicines: Ozempic (weekly injection for type 2 diabetes), Wegovy (weekly injection for weight management), and Rybelsus (daily oral tablet for type 2 diabetes). All three are MHRA-licensed UK prescription medicines. The active ingredient is identical — what differs is the dose, the formulation, and what each is licensed to treat.

For a side-by-side view of the three brands and the drug class semaglutide belongs to, see semaglutide brands and drug class.

How does semaglutide work?

Semaglutide mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). When you eat, your intestine releases GLP-1, which tells your pancreas to make insulin in response to the rising blood sugar, slows your stomach's emptying so you feel full longer, and signals to your brain that the meal has been enough. Natural GLP-1 lasts only a couple of minutes. Semaglutide has been chemically modified so it lasts about a week — meaning its appetite-reducing and glucose-lowering effects are continuous rather than fleeting.

What is the trial evidence for semaglutide?

Semaglutide has the deepest evidence base of any GLP-1 medicine. The STEP programme covered weight management (STEP-1 to 8). The SUSTAIN programme covered type 2 diabetes (SUSTAIN-1 to 7). The SELECT trial covered cardiovascular outcomes in adults with obesity but no diabetes. The FLOW trial covered diabetic kidney disease. STEP-HFpEF covered heart failure with preserved ejection fraction. Each is summarised on this site.

What are the side effects of semaglutide?

The dominant side effects are gastrointestinal: nausea (in roughly 40% of users at higher doses), diarrhoea, constipation and vomiting. Most settle as the dose escalates slowly. Rarer but serious effects include pancreatitis and gallstones — both more likely during periods of rapid weight loss. The dose schedule deliberately escalates over 16 weeks (for Wegovy) to manage tolerability.

FAQs

Are Ozempic, Wegovy and Rybelsus the same thing?: All three contain semaglutide as their active ingredient. They differ in dose strength, what they are licensed for, and how they are taken. Ozempic is licensed for type 2 diabetes (injectable, up to 2 mg weekly). Wegovy is licensed for weight management (injectable, 2.4 mg weekly). Rybelsus is an oral tablet (14 mg daily) licensed for type 2 diabetes.
How does semaglutide cause weight loss?: Semaglutide is a GLP-1 receptor agonist. It mimics a natural gut hormone that signals satiety and slows gastric emptying. Over weeks of weekly injection, it reduces appetite and food intake — clinical trials at the 2.4 mg dose produced around 15% mean weight reduction over 68 weeks.
Does semaglutide help the heart?: Yes — and this is one of the most important recent findings. The SELECT trial (NEJM 2023) showed semaglutide reduced major cardiovascular events by ~20% over almost 4 years in adults with overweight or obesity and established cardiovascular disease. That benefit appears to be larger than what weight loss alone would predict.
How long does it take to work?: Some appetite reduction is noticeable within the first 2-4 weeks. Meaningful weight loss generally becomes visible by month 3, with peak average weight loss reached around month 12-16 on the maintenance dose. Discontinuation is followed by substantial weight regain — typically two-thirds of the lost weight within a year of stopping.
What is GLP-1 semaglutide?: Semaglutide is a synthetic GLP-1 receptor agonist — a lab-made, long-acting version of the natural gut hormone GLP-1 (glucagon-like peptide-1). It is the active ingredient in three MHRA-licensed UK medicines: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management.